CRVO logo

CERVOMED INC

CRVONASDAQ
🏆 #4728 by market capEarnings Nov 5US Equity
$376.29▲ $15.09 (+4.01%)
Simulated price
🔔
Track CRVO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$25M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
100.0%
High
💵FCF Margin
-8673.4%
Thin
⚖️P/S Ratio
76.6x
Expensive
Otter Score
68
Fair
No chart data available for CRVO.

Trading Snapshot

Day Range
$373.61 – $377.82
52-Week Range
$2.13 – $10.00
Volume
$2.22B
Avg Volume
$2.53B
Shares Outstanding
9.3M
Next Earnings
Nov 12, 2026

Fundamentals Snapshot

Annual Revenue
$322,569
Last Q Revenue
$79,363
P/E Ratio
-0.8
P/S Ratio
76.6x
EPS (TTM)
$-2.96
Dividend Yield
0.00%
Dilution (1yr)
+6.3%

Why Investors Own CRVO

  • ✓High-growth profile — revenue up +55.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 68% gross margin and 15% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CRVO logo

CERVOMED INC

CRVO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$28M▲ +55.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$23M▲ +41.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.3M▲ +6.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▼ −$764K YoY
StockOtter · stockotter.space

About CERVOMED INC

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$440.82
▲ +17.1% Upside
High Target$507.03
Low Target$385.34
Based on 33 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

CERVOMED INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift CRVO price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

CERVOMED INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.